Duke Street Bio Announces Appointment of Chief Medical Officer
28 Mar 2023
Executive ChangePhase 2
Duke Street Bio, a UK-based biotech focusing on the discovery of novel precision medicine-based cancer therapies, today announced the strengthening of its executive leadership team with the appointment of Dónal Landers, MB BCh BAO, MBA, DPM, FFPM as Chief Medical Officer. Dr Landers is a highly experienced pharmaceutical physician with a proven track record of leading multiple molecules through early oncology clinical development. Dr Landers combines science, medicine with an entrepreneurial flair to drive translational and clinical drug development in oncology.
After obtaining his primary medical degree from Trinity College, Dublin, Dónal spent several years practicing hospital clinical medicine. He undertook an MBA at University College Dublin before transitioning to senior management at St. James’s Hospital. Dónal then co-founded his own health informatics company developing ‘patient-centric’ mobile technology solutions, enabling patients to collect and monitor their own health data. After a number of years in various technology start-up companies, he joined PricewaterhouseCoopers as a specialist senior consultant and became sectoral lead for the healthcare and pharmaceutical group in Strategy Advisory. Dónal joined AstraZeneca (AZ) in 2010 as pharmaceutical physician in Early Clinical Development (ECD) where he was Senior Director Physician and led multiple targeted therapy clinical programs, including AZ’s first large multi-drug oncology Phase Ib ‘umbrella’ study in urothelial cancer (BISCAY). Most recently Dónal set up his own specialist consulting business, DeLondra Oncology, focusing on candidate selection to Phase II development, specialising in both early clinical and translational drug development in oncology.
Dónal was also co-founder and Strategic Director of the Digital Experimental Cancer Medicine Team based at Cancer Research UK Manchester Institute. This research team was setup to provide next generation patient cancer care using data-driven evidence to enable the transformation of clinical decision-making, the evolution of the role of the patient and the improvement of patient outcomes.
“The addition of Dr Landers comes at an exciting time for Duke Street Bio as we transition our best-in-class PARP1-selective and PARP7 inhibitorPARP7 inhibitor programs into the clinic. We are delighted to have him join the team.” said Alan Wise, CEO Duke Street Bio.
About Duke Street Bio
Duke Street Bio is privately held biotechnology company focused on the development of innovative treatments in oncology. The precision medicine approach in our PARP1-selective inhibitorPARP1-selective inhibitor program exploits tumour genetic vulnerabilities whilst our PARP7 inhibitorPARP7 inhibitor program harnesses the natural power of the body’s immune system to fight cancer. We are committed to developing best-in-class products that fulfil major unmet medical needs.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.